載入中
NASDAQHealthcareBiotechnology
最新資料
US$74.35
+US$1.19 · +1.63%
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
一般交易時段
US$74.35
+US$1.19 · +1.63%
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
82
深度低估
情緒
52
多空交錯
風險
51
風險偏高
動能
40
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
日內區間
目前US$74.35
52週區間
目前US$74.35
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$103
上漲空間 38.53%價格歷史記錄不可用
最高：US$116平均的：US$103最低：US$89.00AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
